Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. Rapid communication.
Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance.
Dysregulation of regulatory CD56(bright) NK cells/T cells interactions in multiple sclerosis.
European Medicines Agency, Scientific Discussion of MabCampath (alemtuzumab)
Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study.
Transdermal Application of Myelin Peptides in Multiple Sclerosis Treatment.
Imaging in Pediatric Demyelinating and Inflammatory Diseases of Brain- Part 2.
Mitoxantrone repression of astrocyte activation: Relevance to multiple sclerosis.
Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients.
Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study.
Estrogen treatment in multiple sclerosis.
Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: The DEFINE study.
Posturography in MS patients treated with high dose methylprednisolone.
A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy.
Functional Characterization of DNA Methylation in the Oligodendrocyte Lineage.
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.
Oral Tolerance Induction in Experimental Autoimmune Encephalomyelitis with Candida utilis Expressing the Immunogenic MOG35-55 Peptide.
Dimethyl Fumarate Ameliorates Lewis Rat Experimental Autoimmune Neuritis and Mediates Axonal Protection.
Genzyme provides update on U.S. LEMTRADA™ filing
Site-Specific PEGylation Enhances the Pharmacokinetic Properties and Antitumor Activity of Interferon Beta-1b.
Effects of fumaric acid esters on blood-brain barrier tight junction proteins.
Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients.
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
Genzyme reports positive top-line results of TOWER, a pivotal phase III trial for AUBAGIO(TM*) (teriflunomide) in relapsing multiple sclerosis
Alterations of the optic pathway between unilateral and bilateral optic nerve damage in multiple sclerosis as revealed by the combined use of advanced diffusion kurtosis imaging and visual evoked potentials.

Pages